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Abstract 
Introduction Acute myeloid leukemia (AML) is a heterogeneous clonal disorder often 
associated with dismal overall survival. The clinical diversity of AML is reflected in the 
range of recurrent somatic mutations in several genes, many of which have a prognostic and 
therapeutic value. Targeted next-generation sequencing of these genes has potential for 
translation into clinical practice. In order to assess this potential, an inter-laboratory 
evaluation of a commercially available AML gene panel across three diagnostic centres in the 
UK and Ireland was performed. 
Methods DNA from six AML patient samples was distributed to each centre and processed 
using a standardised workflow, including a common sequencing platform, sequencing chips 
and bioinformatics pipeline. A duplicate sample in each centre was run to assess intra-
laboratory performance.  
Results An average sample read depth of 2725X (range 629-5600) was achieved using six 
samples per chip, with some variability observed in the depth of coverage generated for 
individual samples and between centres. A total of 16 somatic mutations were detected in the 
six AML samples with a mean of 2.7 mutations per sample (range 1-4) representing nine 
genes on the panel. Allelic frequencies of the mutations ranged from 5.6% - 53.3% (median 
44.4%) with a high level of concordance of these frequencies between centres for mutations 
detected. 
Conclusion In this inter-laboratory comparison, a high concordance, reproducibility and 
robustness was demonstrated using a commercially available next-generation sequencing 
AML gene panel and platform.  
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1. Introduction 
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterised by 
infiltration of the bone marrow, blood and other tissues by abnormal or poorly differentiated 
myeloid cells of the hematopoietic system. Diagnosis is based on bone marrow and peripheral 
blood morphology, immunophenotype and the presence of typical chromosomal alterations or 
recurrent mutations. Treatment for AML patients is primarily based on delivery of an 
intensive course of induction chemotherapy such as cytarabine plus anthracycline followed 
by post remission consolidation chemotherapy. Up to 80% of patients achieve complete 
remission however a significant proportion will eventually relapse [1]. Allogeneic 
transplantation offers the potential of a curative therapy in eligible patients after careful 
assessment of co-existing morbidities based on donor availability and genetic profile. 
Recurrent genetic lesions such as Fms-related tyrosine kinase 3 (FLT3), CCAAT/enhancer 
binding protein-α (CEBPA) and nucleophosmin (NPM1) are commonly used as prognostic 
markers in clinical practice, with markers associated with poor outcome such as tumour 
protein 53 (TP53), additional sex combs like transcriptional regulator (ASXL1) and runt-
related transcription factor 1 (RUNX1) likely to be recommended for stratification in 
forthcoming guidelines [2]. 
Next generation sequencing (NGS) technologies allow massive parallel sequencing of 
multiple DNA regions of interest including large or GC rich genes and offer the potential for 
increased throughput, sensitivity and quantification of variant allelic frequencies relative to 
standard Sanger sequencing. Recent application of genomic techniques such as whole 
genome sequencing have yielded a broad view of the mutational landscape of AML and 
highlighted 25-30 recurrent somatic mutations that can be organised into functional 
categories. These genes encode for transcription factors and tumor suppressors, genes related 
to DNA methylation, hematopoietic cytokine signalling, chromatin modification, the cohesin 
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complex, and the spliceosome complex [3]. Further studies have described patterns of clonal 
and subclonal evolution, mutation clearance rates post induction therapy and the monitoring 
of minimal residual disease [4-7]. Together these advances are helping unravel the potential 
for new personalised therapies and targeted treatments with specific agents used in 
combinations with standard chemotherapy to maintain remission or bridge to transplantation 
[2,8]. The adoption of targeted gene panels comprising a refined set of disease relevant genes 
has shown promise for translation of NGS into clinical practice [9-11]. Here we present an 
inter-laboratory evaluation of a commercially available AML gene panel across three clinical 
diagnostic centres in the UK and Ireland. 
2. Material and Methods 
To evaluate the AML NGS panel, DNA from six pre-characterised AML patients (NPM1 and 
FLT3-ITD mutation status assessed by polymerase chain reaction [PCR] and capillary 
electrophoresis using alternative laboratory methods) was used for quality control (QC#1-6), 
distributed to each centre and processed using standardised workflows for the Ion 
AmpliseqTM AML Panel (Life Technologies/Thermo Fisher Scientific, Paisley, UK) before 
sequencing on an Ion Torrent Personalized Genome Machine (PGMTM, Ion TorrentTM, Life 
Technologies/Thermo Fisher Scientific, Paisley, UK). A designated duplicate sample (QC#3, 
QC#5, and QC#6) was repeated on separate runs in centres 1, 3 and 2 respectively to assess 
intra-laboratory reproducibility. Amplicon libraries covering 19 commonly mutated genes 
mplicated in AML and covering the entire coding region of DNA (cytosine-5-)-
methyltransferase 3-a (DNMT3A), CEBPA, GATA binding protein 2 (GATA2), tet 
methylcytosine dioxygenase 2 (TET2), TP53 and mutational hot-spot regions of ASXL1, B-
raf proto-oncogene, serine/threonine kinase (BRAF), Cbl proto-oncogene, E3 ubiquitin 
protein ligase (CBL), FLT3 (tyrosine kinase domain mutations), isocitrate dehydrogenase 1 
(IDH1), isocitrate dehydrogenase 2 (IDH2), Janus kinase 2 (JAK2), v-kit Hardy-Zuckerman 4 
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feline sarcoma viral oncogene homolog (KIT), Kirsten rat sarcoma viral oncogene homolog 
(KRAS), NPM1, neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), protein 
tyrosine phosphatase, non-receptor type 11 (PTPN11), RUNX1 and Wilms tumour 1 (WT1), 
were generated using 10 ng genomic DNA in each of four primer-pooled reactions generating 
264 amplicons. 
Amplified targets were combined from four pools to two, primer sequences were 
partly digested and barcoded adapters were ligated for sample identification. The resulting 
product was purified using Agencourt® AMPure® XP beads as per manufacturer’s 
instruction (Beckman Coulter, Brea, CA, USA). The unamplified libraries were quantified by 
qPCR with the Ion Library Quantification Kit (Life Technologies/Thermo Fisher Scientific, 
Paisley, UK) and equalised to 100pM prior to combination. Emulsion PCR, recovery and 
enrichment of templated Ion SphereTM particles (ISP) was performed using the Ion 
OneTouchTM 2 System or Ion ChefTM System (automated), before loading onto Ion 318TMv2 
chips and sequencing on the Ion Torrent PGMTM platform with the Ion PGMTM Sequencing 
200 kit v2. Data was reviewed using Torrent SuiteTM software v4.2.1.0 (Thermo Fisher 
Scientific, Life Technologies, Paisley, UK) using a low stringency parameter configuration. 
Samples were uploaded to Ion ReporterTM v4.2 cloud based software (Thermo Fisher 
Scientific, Life Technologies, Paisley, UK) as BAM or VCF files for subsequent variant 
annotation.  
Coverage in highly sampled locations was capped at 2000X to reduce computational 
time. Confident calling of somatic mutations was achieved using an algorithm that excluded 
homozygous or synonymous mutations, variants located within intronic or un-translated 
regions and variants present at a frequency of <5%. Insertions/deletions called using Ion 
ReporterTM were confirmed by reviewing data with the Broad Institute’s Integrative 
Genomics Viewer (IGV) [12].  In addition, AcroMetrix controls (Life Technologies/Thermo 
6 
 
Fisher Scientific), a highly multiplexed QC used to assess the performance of NGS assays, 
was employed in one centre to determine variant detection at low variant allele frequencies 
(VAFs). To maximise confidence in variant calling, a minimum target depth of coverage for 
variant calls was set at 500X based on these data, with potential somatic variants reviewed 
and screened using relevant public databases, such as dbSNP, ClinVar, COSMIC, and 
PubMed. No homozygous mutations of somatic relevance were detected using the 
aforementioned public databases. 
3. Results 
3.1    Platform performance 
Performance of the Ion Torrent platform and workflow at each centre was assessed using the 
quality control data generated for each sample (Supplementary Table 1). Variables assessed 
were the number of reads generated, the number and AQ20 (1% error rate) quality score of 
bases, the average depth of coverage across the bases and the average read length generated. 
A mean read count of 602,354 reads per sample (range 150,312-1,212,941) was generated. 
Mean read length at AQ20 was consistent at 123 bp (CV 3.3%) for all samples analysed. An 
average sample read depth of 2725X (range 629-5600) was achieved using 6 samples on a 
318TMv2 chip, with significant variability observed in the depth of coverage generated for 
individual QC samples and between centres (electronic supplementary Table 1). AcroMetrix 
controls showed detection of applicable variants present in IDH1/2, KIT, NPM1, PTPN11, 
FLT3, TP53, KRAS and NRAS at VAFs of between 5 and 10 % (25 % for NPM1) at 500X 
as expected, 
3.2   Somatic mutation detection 
Unfiltered data files from each centre were downloaded from Ion ReporterTM and analysed 
using the filtering algorithm outlined above. A total of 16 somatic mutations were identified 
in the six AML patient samples tested.   Centres 1 and 3 identified all 16 mutations, whereas 
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Centre 2 identified 15/16 producing analytical specificity for the gene panel of 97.9% (95% 
CI 89-99%)(electronic supplementary Table 2).   A mean of 2.7 somatic mutations were 
detected in each AML patient sample (range 2-6) representing 10 genes on the panel 
(DNMT3A, TET2, NPM1, NRAS, RUNX1, KIT, PTPN11, ASXL1, IDH1, IDH2) with TET2 
and DNMT3A being the most frequent. NPM1 mutations were identified in one of the siz QC 
samples confirming results obtained at diagnosis by standard methodology at the referring 
centre.  In addition two frameshift deletions in ASXL1 not currently represented in COSMIC 
were identified in all centres and confirmed using IGV.  
Allelic frequencies of the 16 mutations detected ranged from 5.6 – 53.3% (median 
44.4%) with a high concordance between centres for mutations detected (Figure 1). Of note, 
Centre 2 did not report detection of the PTPN11 c.215C>A p.Ala72Asp mutation in sample 
three.  Reanalysis of the data confirmed the presence of the missed mutation at a read depth 
of 302X, initially omitted as the read depth of 500X (in italics in electronic supplementary 
Table 2 and Fig 1, mutation number 7. 
.In addition one mutation, a RUNX1 c.167T>C p.Leu56Ser missense mutation 
detected in QC#4 showed a difference in allelic frequency (Figure 2 mutation 17), with 
Centre 1 and 3 detecting the mutation at approximately 50% compared to 24% for Centre 2 
despite deep coverage (>1000 fold) of the sample at this site by all centres. Assessment of 
intra-laboratory reproducibility using duplicate samples showed concordance with results 
generated at all centres (Supplementary Table 2).  
3.3 Reproducibility 
Analysis of duplicate sample data showed both within and between run concordances, with 
the same number of variants detected at similar frequencies by all centres (electronic 
supplementary Table 2). 
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4. Discussion 
There is considerable interest in translating targeted NGS of AML into clinical laboratories 
for routine detection of therapeutically actionable disease mutations [10, 11, 13, 14]. In this 
report, we have evaluated the inter- and intra-laboratory reproducibility and robustness of a 
commercial 19-gene AML panel in three separate clinical centres in the UKand Ireland. 
Performance of the panel was assessed using six AML patient samples run on the Ion 
PGMTM platform across all centres.Ahigh level of concordance was observed, with 15/16 
mutations detected. Centre 2 did not report a PTPN11 c.215C[A p.Ala72Asp mutation that 
was excluded as the number of reads generated for the sample was low (150,312) and the 
subsequent read depth at the target site did not achieve 500X. As a depth of coverage of 500X 
is necessary for confidence in calling low-level mutations (25 mutated reads are required for 
a 5 % burden), it is therefore essential to ensure appropriate coverage of all relevant 
amplicons to enable appropriate interrogation and interpretation of data produced. Improving 
efficiencies during the preanalytic stages could help achieve this and would reduce the 
variability in reads generated between samples and between centres. Optimisation of library 
equalisation or implementation of automated template preparation and chip loading (Ion 
ChefTM) could increase reads generated and improve preanalytical consistency. Reduction of 
sample number per chip or repeat testing and combination of results for samples that prove 
difficult to sequence would help deliver sufficient read depth for further analysis.  
Nevertheless, given the variation in reads generated per sample by each centre, the high 
concordance in the identification and coverage depth of somatic mutations in the samples 
tested proves the capacity of the Ion AmpliseqTM AML Research Panel and Ion Torrent as a 
robust platform for generating reproducible results in a clinical diagnostic setting.  
Incorporation of this gene panel would complement and enhance the armoury of tools 
available for identification of relevant diagnostic and prognostic somatic mutations in AML 
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patients. A limitation of this study was the limited number of genes available for analysis. 
Expansion of the panel to incorporate a greater number of relevant genes mutated in AML 
(e.g. splicing factors) would further improve its applicability.  
5. Conclusion 
The use of targeted panels in AML has the potential to overcome the limitations of standard 
Sanger sequencing in terms of time, the potential to sequence multiple gene targets at once 
and the ability to quantify variant allelic frequencies. In a clinical diagnostic setting these 
benefits translate into additional clinically relevant information and justify the application of 
limited resources to generate relevant information for clinical decision making. The 
implementation of common platforms and workflows to interrogate the mutational profile of 
AML patients will enable standardisation of results and further collaborative efforts between 
centres.  
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Figure legends: 
Figure 1: Allelic frequency of mutations detected in quality-control samples. Mutation 1: 
DNMT3A p.Leu344Gln; Mutation 2: NPM1 p.Trp288fs; Mutation 3: NRAS p.Gly12Asp; 
Mutation 4: NRAS p.Gly12Ser; Mutation 5: TET2 pArg1216Ter; Mutation 6: RUNX1 
p.Arg204Gln; Mutation 7: PTPN11 p.Ala72Asp; Mutation 8: ASXL1 p.Leu890fs; Mutation 
9: DNMT3A p.Arg882His; Mutation 10: IDH1 p.Arg132Cys; Mutation 11: ASXL1 
p.Arg693Ter; Mutation 12: ASXL1 p.Gly966del; Mutation 13: DNMT3A p.Arg882Cys; 
Mutation 14: DNMT3A p.Arg792His; Mutation 15: IDH2, p.Arg172Lys; Mutation 16: 
ASXL1 p.Ser798fs  
Supplementary table legends: 
Supplementary Table 1: Performance variables for Ion Torrent Ampliseq AML Panel across 
six QC samples. 
Supplementary Table 2: Somatic mutations identified in six QC samples. 
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